Sequenom's Q1 Revenues More than Double | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its first-quarter revenues grew 158 percent year over year, driven by growth in its diagnostics business, and particularly from sales of its MaterniT21 Plus test for fetal aneuploidies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.